Maplight Therapeutics (NASDAQ:MPLT) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Maplight Therapeutics (NASDAQ:MPLT) from a hold rating to a sell rating in a research report sent to investors on Saturday.

Several other equities research analysts have also recently weighed in on the company. Stifel Nicolaus began coverage on Maplight Therapeutics in a research note on Friday. They set a “buy” rating and a $28.00 target price for the company. Morgan Stanley started coverage on shares of Maplight Therapeutics in a research note on Friday. They issued an “overweight” rating and a $34.00 price objective for the company. Leerink Partners started coverage on shares of Maplight Therapeutics in a research note on Friday. They set an “outperform” rating and a $30.00 target price on the stock. Finally, Jefferies Financial Group started coverage on Maplight Therapeutics in a research note on Friday. They issued a “buy” rating and a $32.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. According to data from MarketBeat.com, Maplight Therapeutics has a consensus rating of “Buy” and a consensus target price of $31.00.

Maplight Therapeutics Stock Down 7.1%

Shares of NASDAQ:MPLT opened at $13.00 on Friday. Maplight Therapeutics has a 12-month low of $12.92 and a 12-month high of $20.86.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.